Pharmacokinetics of selected antiinfectives during extracorporeal membrane oxygenation (ECMO)

Completed

Conditions: J96.0
Acute respiratory failure

Registration Number: DRKS00010765

Lead Sponsor: niversitätsklinikum Hamburg-EppendorfKlinik für Intensivmedizin

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 44

Inclusion Criteria

Consecutive inclusion of adult patients (Age = 18 years) of both genders, who need an ECMO and receive at least one of the following antiinfective drugs: anidulafungin, ceftazidime, ciprofloxacin, clarithromycin, colistin, linezolid, meropenem, piperacillin/tazobactam, posaconazole, tigecyclin, vancomycin or voriconazole.

Exclusion Criteria

Age < 18 years
missing informed content

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the study is the systematic evaluation of serum levels of different antiinfectives in critically ill patients undergoing ECMO treatment.<br>The main Focus is to Analyse, whether this special patient population is treated appropriately and whether the standard doses of antiinfectives are adequate and can be maintained.<br>

Secondary Outcome Measures

Name	Time	Method
- 28-days mortality, if the patient is treated as an inpatient in the UKE at that timepoint<br>- length of stay in the intensive care unit and in the hospital<br>- Progression parameter of infection markers (leucocytes, CRP, PCT)<br>- infections, that might be present due to potential underdosing of antiinfectives<br>